Results 221 to 230 of about 15,914 (251)

Experimental radioimmunotherapy

Seminars in Radiation Oncology, 2000
Experimental radioimmunotherapy (RIT) studies in animal models have contributed significantly to the design of clinical RIT protocols, although the results have not always been directly translated. Reviewed in this article are current areas of active research in experimental RIT to increase the therapeutic ratio that are likely to have a significant ...
openaire   +2 more sources

Radioimmunodetection and Radioimmunotherapy

Cancer Investigation, 1984
The development of monoclonal antibodies that recognize tumor-associated antigens has led to significantly greater practical possibilities for producing highly specific radiolabeled antibodies for diagnosis and therapy of human tumors. A number of problems remain before this technique will be ready for routine clinical application however.
S M, Larson, J A, Carrasquillo, J C, Reynolds   +2 more
openaire   +2 more sources

Anti-HER2 Radioimmunotherapy

Breast Disease, 2000
HER2/neu is a receptor protein whose overexpression strongly correlates with poor prognosis in breast carcinomas. It is used increasingly as a therapeutic target for breast carcinomas in clinical human trials. In particular, monoclonal antibodies (mAbs) that target HER2/neu have been investigated for therapeutic applications.
M W, Brechbiel, T A, Waldmann
openaire   +2 more sources

Radioimmunotherapy of brain tumor

Neurological Research, 2006
Despite years of intensive research, the prognosis of high-grade gliomas (HGG) remains poor, as these tumors are highly resistant to currently available therapies. Therefore, there is a need for the development of new therapeutic strategies, such as the use of monoclonal antibodies (MoAbs) in association with radioisotopes, in order to achieve better ...
Giovanni, Paganelli, Mirco, Bartolomei, Chiara, Grana, Mahila, Ferrari, Paola, Rocca, Marco, Chinol   +5 more
openaire   +2 more sources

Abscopal effect in radioimmunotherapy

International Immunopharmacology, 2020
Abscopal effect is an interesting phenomenon in radiobiology that causes activation of immune system against cancer cells. Traditionally, this phenomenon was known as a suppressor of non-irradiated tumors or metastasis. However, it can be used as a stimulator of the immune system against primary tumor during radiotherapy.
Milad, Ashrafizadeh, Bagher, Farhood, Ahmed, Eleojo Musa, Shahram, Taeb, Abolhassan, Rezaeyan, Masoud, Najafi   +5 more
openaire   +2 more sources

Fundamentals of radioimmunotherapy

International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
Design of a radioimmunotherapy trial is a complex process. This involves antibody selection, choice of radioisotope, and labeling method. Observation of the behavior of the new radiopharmaceutical involves determination of normal organ and tumor uptake, as well as residence time.
openaire   +2 more sources

Radioimmunotherapy of lymphoma

1993
The development of radiolabeled monoclonal antibodies (MoAb) was a significant advance in the use of these molecules for the treatment of human neoplasms. Unlabeled murine MoAbs had proven to have modest activity against human neoplasms due to (1) the relatively poor interactions between the antibody Fc receptors and human effector cells, and (2) the ...
T M, Kuzel, S T, Rosen
openaire   +2 more sources

Radioimmunotherapy for lymphoma

Current Opinion in Oncology, 1999
After more than a decade of unfulfilled promises, radioimmunotherapy for the treatment of non-Hodgkin's lymphoma has been demonstrated to be efficacious in the treatment of refractory disease. It is likely that in the near future, the Food and Drug Administration will approve one or more radioimmunoconjugates for clinical use.
openaire   +2 more sources

Bifunctional Antibodies for Radioimmunotherapy

Hybridoma, 1995
In two-step targeting technique using bifunctional antibodies, a nonradiolabeled immunoconjugate with slow uptake kinetics (several days) is initially injected, followed by a small radiolabeled hapten with fast kinetics (several hours) that binds to the bispecific immunoconjugate already taken up by the tumor target.
J F, Chatal, A, Faivre-Chauvet, M, Bardies, P, Peltier, E, Gautherot, J, Barbet   +5 more
openaire   +2 more sources

An overview of radioimmunotherapy

Cancer Immunology Immunotherapy, 1991
In reviewing the current state of affairs in radioimmunotherapy the paper focuses on the main difficulties thus far encountered and the procedures designed to avoid or circumvent these problems. The long range beta-emitters 90Y and 188Re have replaced 131I as the isotopes currently receiving most attention for use in radioimmunotherapy, and a range of ...
A, Maraveyas, A A, Epenetos
openaire   +2 more sources